文献速递糖尿病

糖尿病患者肾脏疾病的新疗法

Novel Therapies for Kidney Disease in People With Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

SGLT2抑制剂、肠促胰岛素相关疗法和盐皮质激素受体拮抗剂显示肾脏结局获益,多种其他药物需进一步探索。

要点

  • SGLT2抑制剂在大型跨国试验中改善肾脏结局,包括已确诊DKD患者。
  • 肠促胰岛素相关疗法显示一定肾脏结局改善。
  • 盐皮质激素受体拮抗剂在大型试验中显示多种肾脏结局改善潜力。

核心结论

  • SGLT2抑制剂和肠促胰岛素相关疗法显示获益并与心血管结局改善相关。
  • 盐皮质激素受体拮抗剂是另一类证据日益增加的获益药物。

研究设计与样本

  • 系统化叙述性综述,检索PubMed、Embase(Ovid)、CINAHL和Cochrane数据库(2010年1月至2021年1月)。

主要发现

  • 大型跨国高把握度试验显示SGLT2抑制剂改善肾脏结局,即使已确诊DKD患者亦然。
  • 肠促胰岛素相关疗法试验显示一定肾脏结局改善。
  • 盐皮质激素受体拮抗剂在大型试验中显示多种肾脏结局改善潜力,包括已确诊DKD参与者。
  • Atrasentan、baricitinib等多种药物与部分肾脏终点改善相关但需进一步探索。
  • Bardoxolone methyl与白蛋白尿下降相关但心血管不良事件发生率高限制进一步探索。

关键数值与推荐

  • SGLT2抑制剂、肠促胰岛素相关疗法和盐皮质激素受体拮抗剂显示肾脏结局获益。
  • Selonsertib、allopurinol、praliciguat、palosuran、benfotiamine和diacerein与肾脏结局改善无关。

临床怎么用

  • SGLT2抑制剂和肠促胰岛素相关疗法可用于DKD管理并改善心血管结局。
  • 盐皮质激素受体拮抗剂是DKD治疗中证据增加的另一类药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The increasing burden of diabetic kidney disease (DKD) has led to the discovery of novel therapies. OBJECTIVE: This review aims to summarize the results of recent clinical trials that test the efficacy of potential therapies for DKD. METHODS: A systematized narrative review was performed utilizing the PubMed, Embase (Ovid), CINAHL, and Cochrane databases (January 2010 to January 2021). The included trials assessed the efficacy of specific medications using renal endpoints in adult participants with type 1 or 2 diabetes. RESULTS: Fifty-three trials were identified. Large, multinational, and high-powered trials investigating sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrated improved renal outcomes, even in patients with established DKD. Trials examining incretin-related therapies also showed some improvement in renal outcomes. Additionally, mineralocorticoid receptor antagonists exhibited potential with multiple improved renal outcomes in large trials, including those involving participants with established DKD. Atrasentan, baricitinib, ASP8232, PF-04634817, CCX140-B, atorvastatin, fenofibrate, probucol, doxycycline, vitamin D, omega-3 fatty acids, silymarin, turmeric, total glucosides of paeony, and tripterygium wilfordii Hook F extract were all associated with some improved renal endpoints but need further exploration. While bardoxolone methyl was associated with a decrease in albuminuria, high rates of cardiovascular adverse effects curtailed further exploration into this agent. Selonsertib, allopurinol, praliciguat, palosuran, benfotiamine, and diacerein were not associated with improved renal outcomes. CONCLUSION: Trials have yielded promising results in the search for new therapies to manage DKD. SGLT2 inhibitors and incretin-related therapies have demonstrated benefit and were associated with improved cardiovascular outcomes. Mineralocorticoid receptor antagonists are another class of agents with increasing evidence of benefits.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Khurana N, James S, Coughlan MT, et al. Novel Therapies for Kidney Disease in People With Diabetes. J Clin Endocrinol Metab. 2022. PMID: 34460928. doi:10.1210/clinem/dgab639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。